Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Multi-Modality Imaging in Vasculitis
Allam, Mohamed , Ali, Nima Baba , Mahmoud, Ahmed , Scalia, Isabel G. , Farina, Juan M. , Abbas, Mohammed Tiseer , Pereyra, Milagros , Kamel, Moaz, Awad, Kamal A., Wang, Yuxiang , Barry, Timothy , Huang, Steve S. , Yang, Ming , Jokerst, Clinton, Martinez, Felipe , Arsanjani, Reza , Awad, Kamal , Allam, Mohamed N , Baba Ali, Nima, Mahmoud, Ahmed K , Kamel, Moaz A, Nguyen, Ba D. , Martinez, Felipe , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Scalia, Isabel G , Abbas, Mohammed Tiseer , Awad, Kamal

Mayo Clinic

Diagnostics | April 18, 2024 | Volume: 14 | Issue: 8 | Pages: 838

10.3390/diagnostics14080838 | PMID 38667483 Get It

Systemic vasculitides are a rare and complex group of diseases that can affect multiple organ systems. Clinically, presentation may be vague and non-specific and as such, diagnosis and subsequent management are challenging. These entities are typically classified by the size of vessel involved, including large-vessel vasculitis (giant cell arteritis, Takayasu’s arteritis, and clinically isolated aortitis), medium-vessel vasculitis (including polyarteritis nodosa and Kawasaki disease), and small-vessel vasculitis (granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis). There are also other systemic vasculitides that do not fit in to these categories, such as Behcet’s disease, Cogan syndrome, and IgG4-related disease. Advances in medical imaging modalities have revolutionized the approach to diagnosis of these diseases. Specifically, color Doppler ultrasound, computed tomography and angiography, magnetic resonance imaging, positron emission tomography, or invasive catheterization as indicated have become fundamental in the work up of any patient with suspected systemic or localized vasculitis. This review presents the key diagnostic imaging modalities and their clinical utility in the evaluation of systemic vasculitis.
Clinicopathologic Heterogeneity and Glial Activation Patterns in Alzheimer Disease
Frankenhauser, Isabelle , Peng, Zhongwei , Labuzan, Sydney A. , Boon, Baayla D.C. , Moloney, Christina M. , Pottier, Cyril , Wickland, Daniel P. , Tranovich, Jessica F., Wood, Ashley , Hinkle, Kelly M., Lincoln, Sarah, Spychalla, Anthony J., Przybelski, Scott A. , Kwan, Rain S., Lesser, Elizabeth R. , Carter, Rickey E. , Ross, Owen A. , Lachner, Christian , Ertekin‐Taner, Nilüfer , Ferman, Tanis J. , Fields, Julie A. , Nguyen, Aivi T. , Reichard, R. Ross , Graff‐Radford, Jonathan , Petersen, Ronald C. , Jack, Clifford R. , Kantarci, Kejal , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Lowe, Val J. , Murray, Melissa E. , Kouri, Naomi , Caetano-Anolles, Kelsey, Corriveau-Lecavalier, Nick , Wood, Ashley C., Lincoln, Sarah J, Engelberg-Cook, Erica , Crook, Julia E. , Jack, Clifford R , Ross, Owen A , Carter, Rickey E , Kantarci, Kejal , Day, Gregory S , Murray, Melissa E , Ferman, Tanis J , Nguyen, Aivi T , Pottier, Cyril , Caetano-Anollés, Kelsey , Corriveau‐Lecavalier, Nick , Wood, Ashley C., Senjem, Matthew L. , Schwarz, Christopher G. , Machulda, Mary M. , Ramanan, Vijay K. , Jones, David T. , Boeve, Bradley F. , Knopman, David S. , Duara, Ranjan , Dickson, Dennis W. , Vemuri, Prashanthi

Mayo Clinic

JAMA Neurology | April 15, 2024 | Volume: 81 | Issue: 6 | Pages: 619

10.1001/jamaneurol.2024.0784 | PMID 38619853 Get It

Importance Factors associated with clinical heterogeneity in Alzheimer disease (AD) lay along a continuum hypothesized to associate with tangle distribution and are relevant for understanding glial activation considerations in therapeutic advancement. Objectives To examine clinicopathologic and neuroimaging characteristics of disease heterogeneity in AD along a quantitative continuum using the corticolimbic index (CLix) to account for individuality of spatially distributed tangles found at autopsy. Design, Setting, and Participants This cross-sectional study was a retrospective medical record review performed on the Florida Autopsied Multiethnic (FLAME) cohort accessioned from 1991 to 2020. Data were analyzed from December 2022 to December 2023. Structural magnetic resonance imaging (MRI) and tau positron emission tomography (PET) were evaluated in an independent neuroimaging group. The FLAME cohort includes 2809 autopsied individuals; included in this study were neuropathologically diagnosed AD cases (FLAME-AD). A digital pathology subgroup of FLAME-AD cases was derived for glial activation analyses. Main Outcomes and Measures Clinicopathologic factors of heterogeneity that inform patient history and neuropathologic evaluation of AD; CLix score (lower, relative cortical predominance/hippocampal sparing vs higher, relative cortical sparing/limbic predominant cases); neuroimaging measures (ie, structural MRI and tau-PET). Results Of the 2809 autopsied individuals in the FLAME cohort, 1361 neuropathologically diagnosed AD cases were evaluated. A digital pathology subgroup included 60 FLAME-AD cases. The independent neuroimaging group included 93 cases. Among the 1361 FLAME-AD cases, 633 were male (47%; median [range] age at death, 81 [54-96] years) and 728 were female (53%; median [range] age at death, 81 [53-102] years). A younger symptomatic onset (Spearman ρ = 0.39, P < .001) and faster decline on the Mini-Mental State Examination (Spearman ρ = 0.27; P < .001) correlated with a lower CLix score in FLAME-AD series. Cases with a nonamnestic syndrome had lower CLix scores (median [IQR], 13 [9-18]) vs not (median [IQR], 21 [15-27]; P < .001). Hippocampal MRI volume (Spearman ρ = −0.45; P < .001) and flortaucipir tau-PET uptake in posterior cingulate and precuneus cortex (Spearman ρ = −0.74; P < .001) inversely correlated with CLix score. Although AD cases with a CLix score less than 10 had higher cortical tangle count, we found lower percentage of CD68-activated microglia/macrophage burden (median [IQR], 0.46% [0.32%-0.75%]) compared with cases with a CLix score of 10 to 30 (median [IQR], 0.75% [0.51%-0.98%]) and on par with a CLix score of 30 or greater (median [IQR], 0.40% [0.32%-0.57%]; P = .02). Conclusions and Relevance Findings show that AD heterogeneity exists along a continuum of corticolimbic tangle distribution. Reduced CD68 burden may signify an underappreciated association between tau accumulation and microglia/macrophages activation that should be considered in personalized therapy for immune dysregulation.
The Risk of Epilepsy in Systemic Autoimmune Diseases: A Population-based Study in Olmsted County, Minnesota (P5-14.001)
Hasan, Shemonti , Nguyen, Adam, Achenbach, Sara J., Langenfeld, Hannah, Devine, Michelle F., Crowson, Cynthia S. , Nguyen, Adam, Flanagan, Eoin P. , Dubey, Divyanshu

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206254 Get It

Effect of cerebrovascular risk factors on the prediction of Alzheimer’s disease neuropathologic change using plasma biomarkers (N4.003)
Bermudez, Camilo , Syrjanen, Jeremy A. , Petersen, Ronald C. , Reichard, Ross R., Graff‐Radford, Jonathan , Knopman, David S. , Ramanan, Vijay K. , Jack, Clifford R. , Nguyen, Aivi T. , Kouri, Naomi , Moloney, Christina M. , Algeciras‐Schimnich, Alicia , Murray, Melissa E. , Mielke, Michelle M. , Vemuri, Prashanthi

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204751 Get It

Enhancing Undergraduate Medical Student Neurology Exposure via the Texas A&M College of Medicine’s Student Interest Group in Neurology (SIGN) Results in Higher Neurology Residency Matches (P10-7.007)
Ramy, Maya, Garg, Tanu , Ramy, Maya , Nguyen, Ryan

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204486 Get It

Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model
Hou, Jinchao , Chen, Yun , Cai, Zhangying , Heo, Gyu Seong , Yuede, Carla M. , Wang, Z , Lin, Kent , Saadi, Fareeha , Tršan, Tihana , Nguyen, Aivi T. , Constantopoulos, Eleni , Larsen, Rachel A. , Zhu, Yiyang , Wagner, Nicole D. , McLaughlin, Nolan, Kuang, Xinyi Cynthia, Barrow, Alexander D. , Zhou, Yingyue , Gilfillan, Susan , Gross, Michael L. , Brioschi, Simone , Liu, Yongjian , Wang, Zuoxu , Li, Dian , Zhou, Yingyue , Wang, Shoutang , Gilfillan, Susan , Gross, Michael L , Brioschi, Simone , Liu, Yongjian , Holtzman, David M , Colonna, Marco , Nguyen, Aivi T , Holtzman, David M. , Colonna, Marco

Mayo Clinic

Science Translational Medicine | April 3, 2024 | Volume: 16 | Issue: 741 | Pages: No page available

10.1126/scitranslmed.adj9052 | PMID 38569016 Get It

Microglia help limit the progression of Alzheimer’s disease (AD) by constraining amyloid-β (Aβ) pathology, effected through a balance of activating and inhibitory intracellular signals delivered by distinct cell surface receptors. Human leukocyte Ig-like receptor B4 (LILRB4) is an inhibitory receptor of the immunoglobulin (Ig) superfamily that is expressed on myeloid cells and recognizes apolipoprotein E (ApoE) among other ligands. Here, we find that LILRB4 is highly expressed in the microglia of patients with AD. Using mice that accumulate Aβ and carry a transgene encompassing a portion of the LILR region that includes LILRB4 , we corroborated abundant LILRB4 expression in microglia wrapping around Aβ plaques. Systemic treatment of these mice with an anti-human LILRB4 monoclonal antibody (mAb) reduced Aβ load, mitigated some Aβ-related behavioral abnormalities, enhanced microglia activity, and attenuated expression of interferon-induced genes. In vitro binding experiments established that human LILRB4 binds both human and mouse ApoE and that anti-human LILRB4 mAb blocks such interaction. In silico modeling, biochemical, and mutagenesis analyses identified a loop between the two extracellular Ig domains of LILRB4 required for interaction with mouse ApoE and further indicated that anti-LILRB4 mAb may block LILRB4-mApoE by directly binding this loop. Thus, targeting LILRB4 may be a potential therapeutic avenue for AD.
Risk Factors for Thyroid Dysfunction in Pregnancy: An Individual Participant Data Meta-Analysis
Osinga, J. , Liu, Yindi , Vafeiadi, Marina , Tao, Fangbiao , López‐Bermejo, Abel , Boucai, Laura , Hisada, Aya , Yoshinaga, Jun , Broeren, Maarten A.C., Itoh, Sachiko, Kishi, Reiko , Ashoor, Ghalia, Veltri, Flora, Lu, Xuemian , Taylor, Peter , Chatzi, Leda , Grineva, Elena , Ghafoor, Farkhanda, Pirzada, Amna, Kianpour, Maryam , Oken, Emily , Suvanto, Eila, Irizar, Amaia , Boelaert, Kristien , Brenta, Gabriela , Dhillon‐Smith, Rima , Dosiou, Chrysoula , Eaton, Jennifer L., Guan, Haixia , Nguyen, Caroline T. , Pop, Victor J.M. , Walsh, John P. , D’Alton, Mary E. , Carty, David , Delles, Christian , Alexander, Erik K. , Pearce, Elizabeth N. , Derakhshan, Arash , Korevaar, Tim I.M. , Osinga, Joris A J , Boucai, Laura , Feldt-Rasmussen, Ulla , Brenta, Gabriela , Guan, Haixia , Lee, Sun Y , Walsh, John P , Nelson, Scott McGill , Bliddal, Sofie , Pearce, Elizabeth N , Taylor, Peter N , López-Bermejo, Abel , Oken, Emily , Dosiou, Chrysoula , Männistö, Tuija , Vaidya, Bijay , Vrijkotte, Tanja G. M. , Mosso, Lorena , Bassols, Judit , Aminorroaya, Ashraf , Chen, Liangmiao , Brown, Suzanne J , Popova, Polina , Hattersley, Andrew T. , Rebagliato, Marisa , Galán, Isolina Riaño , Vrijheid, Martine , Delgado-Saborit, Juana María , Fernández‐Somoano, Ana , Santa‐Marina, Loreto , Maraka, Spyridoula , Morris, Lilah F. , Shan, Zhongyan , Guxens, Mònica , Nicolaides, Kypros H. , Visser, W. Edward , Nelson, Scott M. , Chaker, Layal , Richards, C. Sue , Peeters, Robin P. , Bliddal, Sofie , Huang, Kun , Poppe, Kris Gustave

Mayo Clinic

Thyroid® | March 28, 2024 | Volume: 34 | Issue: 5 | Pages: 646-658

10.1089/thy.2023.0646 | PMID 38546971 Get It

Background: International guidelines recommend targeted screening to identify gestational thyroid dysfunction. However, currently used risk factors have questionable discriminative ability. We quantified the risk for thyroid function test abnormalities for a subset of risk factors currently used in international guidelines. Methods: We included prospective cohort studies with data on gestational maternal thyroid function and potential risk factors (maternal age, body mass index [BMI], parity, smoking status, pregnancy through in vitro fertilization, twin pregnancy, gestational age, maternal education, and thyroid peroxidase antibody [TPOAb] or thyroglobulin antibody [TgAb] positivity). Exclusion criteria were pre-existing thyroid disease and use of thyroid interfering medication. We analyzed individual participant data using mixed-effects regression models. Primary outcomes were overt and subclinical hypothyroidism and a treatment indication (defined as overt hypothyroidism, subclinical hypothyroidism with thyrotropin >10 mU/L, or subclinical hypothyroidism with TPOAb positivity). Results: The study population comprised 65,559 participants in 25 cohorts. The screening rate in cohorts using risk factors currently recommended (age >30 years, parity ≥2, BMI ≥40) was 58%, with a detection rate for overt and subclinical hypothyroidism of 59%. The absolute risk for overt or subclinical hypothyroidism varied <2% over the full range of age and BMI and for any parity. Receiver operating characteristic curves, fitted using maternal age, BMI, smoking status, parity, and gestational age at blood sampling as explanatory variables, yielded areas under the curve ranging from 0.58 to 0.63 for the primary outcomes. TPOAbs/TgAbs positivity was associated with overt hypothyroidism (approximate risk for antibody negativity 0.1%, isolated TgAb positivity 2.4%, isolated TPOAb positivity 3.8%, combined antibody positivity 7.0%; p < 0.001), subclinical hypothyroidism (risk for antibody negativity 2.2%, isolated TgAb positivity 8.1%, isolated TPOAb positivity 14.2%, combined antibody positivity 20.0%; p < 0.001) and a treatment indication (risk for antibody negativity 0.2%, isolated TgAb positivity 2.2%, isolated TPOAb positivity 3.0%, and combined antibody positivity 5.1%; p < 0.001). Twin pregnancy was associated with a higher risk of overt hyperthyroidism (5.6% vs. 0.7%; p < 0.001). Conclusions: The risk factors assessed in this study had poor predictive ability for detecting thyroid function test abnormalities, questioning their clinical usability for targeted screening. As expected, TPOAb positivity (used as a benchmark) was a relevant risk factor for (subclinical) hypothyroidism. These results provide insights into different risk factors for gestational thyroid dysfunction.
NAB2::STAT6 fusions and genome‐wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors
Eschbacher, Kathryn L. , Tran, Quynh T. , Moskalev, Evgeny A. , Jenkins, Sarah M. , Fritchie, Karen , Stoehr, Robert , Caron, Alissa, Link, Michael J., Brown, Paul D. , Guajardo, Andrew, Wu, Ashley, Louis, David N. , Kaplan, Alexander , Ferrarese, Fabio, Raleigh, David R. , Nguyen, Minh , Gross, John , Vega, Jose Velazquez, Haller, Florian , Louis, David N , Giannini, Caterina , Link, Michael J. , Brat, Daniel J. , Santagata, Sandro , Brastianos, Priscilla K. , Alexander, Brian M. , Rossi, Sabrina , Vega, José E. Velázquez , Rodríguez, Fausto J. , Perry, Arie , Martinez‐Lage, Maria , Orr, Brent A. , Giannini, Caterina

Mayo Clinic

Brain Pathology | March 25, 2024 | Volume: 34 | Issue: 6 | Pages: No page available

10.1111/bpa.13256 | PMID 38523251 Get It

AbstractMeningeal solitary fibrous tumors (SFT) are rare and have a high frequency of local recurrence and distant metastasis. In a cohort of 126 patients (57 female, 69 male; mean age at surgery 53.0 years) with pathologically confirmed meningeal SFTs with extended clinical follow‐up (median 9.9 years; range 15 days–43 years), we performed extensive molecular characterization including genome‐wide DNA methylation profiling (n = 80) and targeted TERT promoter mutation testing (n = 98). Associations were examined with NAB2::STAT6 fusion status (n = 101 cases; 51 = ex5‐7::ex16‐17, 26 = ex4::ex2‐3; 12 = ex2‐3::exANY/other and 12 = no fusion) and placed in the context of 2021 Central Nervous System (CNS) WHO grade. NAB2::STAT6 fusion breakpoints (fusion type) were significantly associated with metastasis‐free survival (MFS) (p = 0.03) and, on multivariate analysis, disease‐specific survival (DSS) when adjusting for CNS WHO grade (p = 0.03). DNA methylation profiling revealed three distinct clusters: Cluster 1 (n = 38), Cluster 2 (n = 22), and Cluster 3 (n = 20). Methylation clusters were significantly associated with fusion type (p < 0.001), with Cluster 2 harboring ex4::ex2‐3 fusion in 16 (of 20; 80.0%), nearly all TERT promoter mutations (7 of 8; 87.5%), and predominantly an “SFT” histologic phenotype (15 of 22; 68.2%). Clusters 1 and 3 were less distinct, both dominated by tumors having ex5‐7::ex16‐17 fusion (respectively, 25 of 33; 75.8%, and 12 of 18; 66.7%) and with variable histological phenotypes. Methylation clusters were significantly associated with MFS (p = 0.027), but not overall survival (OS). In summary, NAB2::STAT6 fusion type was significantly associated with MFS and DSS, suggesting that tumors with an ex5::ex16‐17 fusion may have inferior patient outcomes. Methylation clusters were significantly associated with fusion type, TERT promoter mutation status, histologic phenotype, and MFS.
Abstract 7325: Integration of functional data to classify BRCA1/2 missense variants: An ENIGMA project
Lyra, Paulo C. , Dalcolmo, Lucas, Brito, Samuel Gomes, Nguyen, Nam Phuong N. , Oliveira, Geise de, Siva, Joao Paulo da, Taneja, Tanisha, Rossing, Maria , Hazra, Aditi , Caputo, Sandrine M. , Millot, Gaël A. , Yie, Joanne NgeowYuen, Cline, Melissa , Carlsen, Rachael, Josef, Vijay, Morais Lyra, Paulo Cilas , Parsons, Michael T. , Nepomuceno, Thales C. , Caleca, Laura , Hu, Chunling , Richardson, Marcy E , Martins, Alexandra , Yie, Joanne Ngeow Yuen, Carvalho, Marcelo A. , Radice, Paolo , Mesman, Romy L.S. , Zampiga, Valentina , Villani, Rehan Marie , Sharan, Shyam K. , Michailidou, Kyriaki , Spurdle, Amanda B. , Couch, Fergus J. , Vreeswijk, Maaike P.G. , Monteiro, Álvaro N.A.

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 7325-7325

10.1158/1538-7445.am2024-7325 Get It

Abstract The success of precision cancer prevention and treatment hinges on accurate discrimination between benign and pathogenic germline alleles in cancer susceptibility genes. Variants of uncertain clinical significance (VUS) present a challenge for cancer risk assessment and functional data will be essential to resolve many VUS. To address this, we developed a cloud-based environment to collate, curate, integrate and analyze all published functional data related to BRCA1 and BRCA2 missense VUS. Then, functional evidence criteria for pathogenicity were determined for each assay using the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) classification guidelines and ClinGen criteria. Our approach involved retrieving published articles reporting one or more functional assays of BRCA1/2 missense variants reporting variant impact on various biochemical and cell biological functions. Functional results were recorded using original authors' thresholds and categories, then converted to ordinal variables to harmonize: [0 = no functional impact], [1 = intermediate impact], and [2 = functional impact]. For BRCA1, we updated our previous published integration (Genet Med. 2021;23:306-315) with 14 additional publications, collating results from 53 instances of functional assays reporting functional data on 3,219 unique missense variants. For BRCA2, 28 publications were identified reporting data from 141 instances of functional assays on 4,759 unique missense variants. Utilizing a panel of 542 and 396 known pathogenic and benign reference variants for BRCA1 and BRCA2, respectively, we determined the sensitivity, specificity, and ACMG/AMP odds of pathogenicity for each instance of the assay. The remaining variants were assigned a relevant functional assay code weight for each assay instance. Our study successfully derived ACMG/AMP evidence strength from functional data for 3,040 BRCA1 (94% of 3,219) and 2,704 BRCA2 (57% of 4,759) missense variants. This comprehensive work underscores the utility of functional data in informing classification of BRCA1 and BRCA2 missense VUS. Citation Format: Paulo Lyra, Lucas Dalcolmo, Michael Parsons, Thales Nepomuceno, Samuel Brito, Nam Phuong N. Nguyen, Geise de Oliveira, Joao Paulo da Siva, Laura Caleca, Tanisha Taneja, Chunling Hu, Marcy Richardson, Maria Rossing, Aditi Hazra, Alexandra Martins, Sandrine Caputo, Gael A. Millot, Joanne NgeowYuen Yie, Marcelo A. Carvalho, Melissa Cline, Paolo Radice, Rachael Carlsen, Romy Mesman, Valentina Zampiga, Rehan Villani, Vijay Josef, Shyam Sharan, Kyriaki Michailidou, Amanda B. Spurdle, Fergus Couch, Maaike P.G. Vreeswijk, Alvaro N. Monteiro. Integration of functional data to classify BRCA1/2 missense variants: An ENIGMA project [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7325.
Abstract 1434: Modeling the 3q26 OncCassette using genetically engineered mice
Weems, Capella, Jamieson, Lee, Nguyen, Duy T. , Justilien, Verline , Murray, Nicole R., Fields, Alan P. , Meneses, Kayleah M.

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 1434-1434

10.1158/1538-7445.am2024-1434 Get It

Abstract Lung squamous cell carcinoma (LUSC) is a devastating disease, accounting for ~30% of all lung cancer diagnoses and ~40,000 deaths annually in the United States alone. LUSC patients suffer from high prevalence of relapse and a dismal 5-year survival of only ~24%. The lack of animal models that reflect the salient features of human disease to assess the safety and efficacy of drugs, and to explore the underlying molecular mechanisms of LUSC tumor biology, is a major impediment for LUSC patients. We have identified concomitant 3q26 copy number gain (CNG) and TP53 loss as a defining genetic alteration present in ~90% of LUSC tumors. Furthermore, we have identified and characterized three 3q26 oncogenes (PRKCI, ECT2 and SOX2) that genetically and biochemically collaborate to drive LUSC tumor formation. Using syngeneic mouse modeling, we have demonstrated that coordinate overexpression of Prkci, Ect2 and Sox2, and loss of Trp53 in ex vivo cultures of lung basal stem cells (LBSCs; a cell of origin for LUSC) drives transformation of these cells into tumors of exclusively LUSC histopathology. These findings lead to the hypothesis that PRKCI, ECT2 and SOX2 represent a multigenic driver of 3q26 CNG-driven LUSC, which we term the 3q26 OncCassette. Based in these findings, we have developed and begun characterizing the first autochthonous genetically engineered mouse model (GEMM) to study 3q26 OncCassette-driven tumorigenesis. Our novel immune competent GEMM will provide critical insight into tumor initiation and progression of preneoplastic lesions to malignant LUSC and allow characterization of the immune landscape in these tumors. Citation Format: Kayleah M. Meneses, Yi Liu, Capella R. Weems, Lee Jamieson, Duy T. Nguyen, Verline Justilien, Nicole R. Murray, Alan P. Fields. Modeling the 3q26 OncCassette using genetically engineered mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1434.